

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**SCHEDULE 13G**

Under the Securities Exchange Act of 1934  
(Amendment No. 1 )\*

---

**HELIUS MEDICAL TECHNOLOGIES, INC.**

(Name of Issuer)

**Class A Common Stock, no par value**  
(Title of Class of Securities)

**42328V504**  
(CUSIP Number)

**December 31, 2017**  
(Date of Event Which Requires Filing of this Statement)

---

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
- Rule 13d-1(c)
- Rule 13d-1(d)

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

---

---

(1)	Names of reporting persons Philippe Deschamps	
(2)	Check the appropriate box if a member of a group (see instructions)  (a) <input type="checkbox"/> (b) <input type="checkbox"/>	
(3)	SEC use only	
(4)	Citizenship or place of organization United States	
Number of shares beneficially owned by each reporting person with:	(5)	Sole voting power 1,268,416
	(6)	Shared voting power 0
	(7)	Sole dispositive power 1,268,416 (see Item 4(a))
	(8)	Shared dispositive power 0
(9)	Aggregate amount beneficially owned by each reporting person 1,268,416 (see Item 4(a))	
(10)	Check if the aggregate amount in Row (9) excludes certain shares (see instructions)  <input type="checkbox"/>	
(11)	Percent of class represented by amount in Row (9) 6.1% (see Item 4(b))	
(12)	Type of reporting person (see instructions) IN	

**Item 1.**

(a) Name of Issuer:

Helius Medical Technologies, Inc.

---

Address of Issuer's Principal Executive Offices:

(b) 642 Newtown Yardley Road, Suite 100  
Newtown, Pennsylvania, 18940

---

**Item 2.**

(a) Name of Person Filing:

Philippe Deschamps

---

(b) Address of Principal Business Office or, if none, Residence:

208 Palmer Aly  
Newtown, PA 18940

---

(c) Citizenship:

United States

---

(d) Title of Class of Securities:

Class A Common Stock, no par value

---

(e) CUSIP Number:

42328V504

**Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:**

- (a)  Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
- (b)  Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
- (c)  Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
- (d)  Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
- (e)  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
- (f)  An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
- (g)  A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
- (h)  A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i)  A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- (j)  A non-U.S. institution in accordance with §240.13d-1(b)(ii)(J);
- (k)  Group, in accordance with §240.13d-1(b)(1)(ii)(K).
-

If filing as a non-U.S. institution in accordance with §240.13d -1(b)(1)(ii)(J), please specify the type of xxxx institution:

**Item 4. Ownership**

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a) Amount beneficially owned:

As of December 31, 2017 Philippe Deschamps (the "Reporting Person") held 1,268,416 shares of the Class A Common Stock ("Common Stock") of Heliuss Medical Technologies, Inc. (the "Issuer") consisting of (i) 666,911 shares of Common Stock held by Deschamps Global Healthcare Commercialization Services, LLC (the "LLC"). The Reporting Person is the sole member of the LLC; (ii) 25,510 immediately exercisable Warrants to purchase Common Stock held by the LLC; (iii) 5,018 immediately exercisable Warrants to purchase Common Stock held directly by the Reporting Person; (iv) 10,977 shares of Common Stock held directly by the Reporting Person; and (v) options to purchase an aggregate of 560,000 shares of Common Stock exercisable within 60 days of December 31, 2017 directly held by the Reporting Person.

**All share numbers in this Form 13G give retroactive effect to the Issuer's 5-for-1 reverse stock split effected January 22, 2018 (the "Stock Split")**

(b) Percent of class:

The information contained on the cover pages to this Schedule 13G is incorporated herein by reference. The percentage amount is calculated based on (i) 20,178,225 shares of Common Stock outstanding as of January 22, 2018 as reported in the Issuer's Form 8-K giving effect to the Stock Split, as filed with the Securities and Exchange Commission on January 23, 2018, and (ii) an aggregate of 590,528 shares of Common Stock exercisable within 60 days of December 31, 2017 after giving effect to the Stock Split.

(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote

The information contained on the cover page to this Schedule 13G is incorporated herein by reference.

(ii) Shared power to vote or to direct the vote

The information contained on the cover page to this Schedule 13G is incorporated herein by reference.

(iii) Sole power to dispose or to direct the disposition of

The information contained on the cover page to this Schedule 13G is incorporated herein by reference.

(iv) Shared power to dispose or to direct the disposition of

The information contained on the cover page to this Schedule 13G is incorporated herein by reference.

CUSIP No.

**Item 5. Ownership of Five Percent or Less of a Class**

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following[].

**Item 6. Ownership of More than Five Percent on Behalf of Another Person**

Not applicable

**Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person**

Not applicable

**Item 8. Identification and Classification of Members of the Group**

Not applicable

**Item 9. Notice of Dissolution of Group**

Not applicable

**Item 10. Certification**

Not applicable

---

CUSIP No.

**Signature**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 14, 2018

/s/ Philippe Deschamps  
By: Philippe Deschamps

---